In a recent study, a novel method was introduced to use NETs as anti-tumor drug delivery vehicles by re-engineering neutrophils to express the apoptosis-inducing chimeric eGFP-TRAIL protein on NETs, which can simultaneously entrap and kill tumor cells while reserving their antibacterial capabilities (121), making NETs a promising candidate for the delivery of antitumoral agents. Here, TNFSF10 is linked to neoplasm.